Discontinuation of ASP2016 Development for Friedreich Ataxia-Associated Cardiomyopathy
A drug-specific development program for ASP2016, a gene therapy, whose development for cardiomyopathy associated with Friedreich ataxia was discontinued in fiscal 2025.
Companies1How many companies write about this.
Threads1One company can carry more than one thread here.